Helen Torley - 02 Mar 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ James R. Oehler, Attorney-in-Fact
Issuer symbol
HALO
Transactions as of
02 Mar 2026
Net transactions value
-$3,476,157
Form type
4
Filing time
04 Mar 2026, 18:56:16 UTC
Previous filing
24 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Torley Helen PRESIDENT AND CEO, Director C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO /s/ James R. Oehler, Attorney-in-Fact 04 Mar 2026 0001528185

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise +20,000 +2.6% $12.07* 787,780 02 Mar 2026 Direct F1
transaction HALO Common Stock Sale $283,708 -4,100 -0.52% $69.20 783,680 02 Mar 2026 Direct F1, F2
transaction HALO Common Stock Sale $1,069,460 -15,322 -2% $69.80 768,358 02 Mar 2026 Direct F1, F3
transaction HALO Common Stock Sale $40,726 -578 -0.08% $70.46 767,780 02 Mar 2026 Direct F1, F4
transaction HALO Common Stock Options Exercise +20,000 +2.6% $12.07* 787,780 03 Mar 2026 Direct F1
transaction HALO Common Stock Sale $928,167 -13,481 -1.7% $68.85 774,299 03 Mar 2026 Direct F1, F5
transaction HALO Common Stock Sale $451,982 -6,519 -0.84% $69.33 767,780 03 Mar 2026 Direct F1, F6
transaction HALO Common Stock Options Exercise +10,000 +1.3% $12.07* 777,780 04 Mar 2026 Direct F1
transaction HALO Common Stock Sale $512,620 -7,329 -0.94% $69.94 770,451 04 Mar 2026 Direct F1, F7
transaction HALO Common Stock Sale $189,494 -2,671 -0.35% $70.94 767,780 04 Mar 2026 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise -20,000 -9.9% $12.07* 181,923 02 Mar 2026 Common Stock 20,000 $12.07 Direct F1, F9
transaction HALO Option to Purchase Common Stock Options Exercise -20,000 -11% $12.07* 161,923 03 Mar 2026 Common Stock 20,000 $12.07 Direct F1, F9
transaction HALO Option to Purchase Common Stock Options Exercise -10,000 -6.2% $12.07* 151,923 04 Mar 2026 Common Stock 10,000 $12.07 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
F2 Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.375 to $69.370. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.380 to $70.340. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.380 to $70.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.220 to $69.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.220 to $69.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7 Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $70.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8 Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.400 to $71.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9 Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.